Back

A CTC Model Uncovers Metastatic Drivers and Prognostic Markers in Breast Cancer

Fernandez-Santiago, C.; Martinez-Pena, I.; Parames, M.; Rodriguez, M.; Hurtado, P.; Abuin, C.; Costa, C.; Davila Ibanez, A. B.; Lopez-Lopez, R.; Pineiro, R.

2025-01-17 oncology
10.1101/2025.01.16.25320597 medRxiv
Show abstract

BackgroundCirculating tumor cells (CTCs) and CTC-clusters are pivotal in the metastatic process of breast cancer (BC). Owing to their low frequency, models replicating their biology should provide a robust platform for investigating the molecular mechanisms driving metastasis and identifying new biomarkers. We established and characterized a CTC-derived cell model from a mouse xenograft to explore its metastatic behavior and molecular profile, which allowed us to investigate the expression and prognostic significance of a set of genes associated with the metastatic potential of CTCs. MethodsThe CTC line (mCTC) derived from a MDA-MB-231 mouse xenografts was used in comparative functional analyses including cell cycle evaluation, colony formation, invasion, adhesion, and metastatic competency in zebrafish models. Transcriptomic profiling and functional assays were conducted to identify candidate genes and understand their roles in metastasis. Moreover, publicly available gene expression datasets of CTCs, CTC-clusters, and tumor tissue, from GEO and TCGA, were analyzed for the identification of a gene signature that was correlated with survival data. The signature was validated in an independent cohort. ResultsCompared with MDA-MB-231 cells, mCTC cells presented enhanced colony formation, invasion, and adhesion, and increased dissemination and survival in zebrafish. Transcriptomic analysis revealed that SPARC was significantly upregulated. Functional assays showed that SPARC overexpression was correlated with increased invasion and migration. Analysis of public datasets confirmed the high expression of SPARC in BC CTCs and CTC-clusters. Additionally, a 4-gene signature involving SPARC, THBS1, VCL, and HSP90AB1 was identified that demonstrated strong prognostic value, predicting shorter overall and distant metastasis-free survival in the primary tumor setting. Validation cohorts confirmed its ability to distinguish high-risk patients. Elevated expression of the 4-gene signature in CTCs was also indicative of increased mortality risk. ConclusionmCTC exhibit distinct metastatic traits and molecular characteristics, highlighting a possible role of SPARC in CTC biology and its potential as a prognostic marker in BC metastasis. The identified 4-gene signature provides a robust prognostic tool for assessing patient risk and guiding therapeutic strategies. Further investigations into the mechanistic role of SPARC may reveal new therapeutic targets for managing BC progression.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
OncoImmunology
24 papers in training set
Top 0.1%
12.9%
2
Cancers
213 papers in training set
Top 0.2%
12.6%
3
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.1%
11.9%
4
Frontiers in Oncology
103 papers in training set
Top 0.5%
6.2%
5
Translational Oncology
21 papers in training set
Top 0.1%
5.5%
6
eLife
5828 papers in training set
Top 27%
4.3%
50% of probability mass above
7
Cancer Letters
35 papers in training set
Top 0.2%
3.4%
8
Frontiers in Immunology
638 papers in training set
Top 4%
3.2%
9
Oncogene
85 papers in training set
Top 0.6%
3.2%
10
International Journal of Cancer
49 papers in training set
Top 0.3%
3.2%
11
Scientific Reports
3612 papers in training set
Top 51%
1.9%
12
Molecular Oncology
55 papers in training set
Top 0.6%
1.7%
13
Breast Cancer Research
36 papers in training set
Top 0.3%
1.7%
14
Nature Communications
5641 papers in training set
Top 45%
1.7%
15
iScience
1154 papers in training set
Top 17%
1.7%
16
Cell Death & Differentiation
48 papers in training set
Top 0.5%
1.7%
17
Frontiers in Cell and Developmental Biology
233 papers in training set
Top 3%
1.5%
18
Cancer Gene Therapy
11 papers in training set
Top 0.1%
1.5%
19
Cancer Research
130 papers in training set
Top 2%
1.5%
20
Communications Biology
993 papers in training set
Top 22%
1.1%
21
International Journal of Molecular Sciences
494 papers in training set
Top 13%
1.0%
22
British Journal of Cancer
49 papers in training set
Top 2%
0.8%
23
npj Breast Cancer
23 papers in training set
Top 0.5%
0.8%
24
Journal of Clinical Investigation
179 papers in training set
Top 5%
0.8%
25
EMBO Molecular Medicine
95 papers in training set
Top 3%
0.8%
26
Theranostics
37 papers in training set
Top 1%
0.8%
27
Cell Death & Disease
126 papers in training set
Top 4%
0.6%
28
JCI Insight
277 papers in training set
Top 9%
0.6%
29
European Journal of Cancer
11 papers in training set
Top 0.4%
0.6%